Personalizing Medical Treatment Decisions: Integrating Meta-analytic Treatment Comparisons with Patient-Specific Risks and Preferences
Abstract/Contents
- Abstract
- Background. Network meta-analyses (NMAs) that compare treatments for a given condition allow physicians to identify which treatments have higher or lower probabilities of reducing the risks of disease complications or increasing the risks of treatment side effects. Translating these data into personalized treatment plans requires integration of NMA data with patient-specific pretreatment risk estimates and preferences regarding treatment objectives and acceptable risks. Methods. We introduce a modeling framework to integrate data probabilistically from NMAs with data on individualized patient risk estimates for disease outcomes, treatment preferences (such as willingness to incur greater side effects for increased life expectancy), and risk preferences. We illustrate the modeling framework by creating personalized plans for antipsychotic drug treatment and evaluating their effectiveness and cost-effectiveness. Results. Compared with treating all patients with the drug that yields the greatest quality-adjusted life-years (QALYs) on average (amisulpride), personalizing the selection of antipsychotic drugs for schizophrenia patients over the next 5 years would be expected to yield 0.33 QALYs (95% credible interval [crI]: 0.30–0.37) per patient at an incremental cost of $4849/QALY gained (95% crI: dominant–$12,357), versus 0.29 and 0.04 QALYs per patient when accounting for only risks or preferences, respectively, but not both. Limitations. The analysis uses a linear, additive utility function to reflect patient treatment preferences and does not consider potential variations in patient time discounting. Conclusions. Our modeling framework rigorously computes what physicians normally have to do mentally. By integrating 3 key components of personalized medicine—evidence on efficacy, patient risks, and patient preferences—the modeling framework can provide personalized treatment decisions to improve patient health outcomes.
Description
| Type of resource | software, multimedia |
|---|---|
| Date created | 2019 |
Creators/Contributors
| Author | Weyant, Christopher |
|---|---|
| Author | Brandeau, Margaret |
| Author | Basu, Sanjay |
Subjects
| Subject | medical decision making |
|---|---|
| Subject | personalized medicine |
| Subject | schizophrenia |
Bibliographic information
| Related Publication | Weyant, C., Brandeau, M. L., & Basu, S. (2019). Personalizing Medical Treatment Decisions: Integrating Meta-analytic Treatment Comparisons with Patient-Specific Risks and Preferences. Medical Decision Making, 39(8), 998–1009. https://doi.org/10.1177/0272989X19884927 |
|---|---|
| Location | https://purl.stanford.edu/rf973hg5932 |
Access conditions
- Use and reproduction
- User agrees that, where applicable, content will not be used to identify or to otherwise infringe the privacy or confidentiality rights of individuals. Content distributed via the Stanford Digital Repository may be subject to additional license and use restrictions applied by the depositor.
- License
- This work is licensed under a Creative Commons Attribution Non Commercial Share Alike 3.0 Unported license (CC BY-NC-SA).
Preferred citation
- Preferred Citation
- Weyant, Christopher and Brandeau, Margaret and Basu, Sanjay. (2019). Personalizing Medical Treatment Decisions: Integrating Meta-analytic Treatment Comparisons with Patient-Specific Risks and Preferences. Stanford Digital Repository. Available at: https://purl.stanford.edu/rf973hg5932
Collection
Stanford Research Data
View other items in this collection in SearchWorksContact information
- Contact
- cweyant@stanford.edu
Also listed in
Loading usage metrics...